Objective: To examine the efficacy of once-monthly paliperidone palmitate (PP1M) on symptoms and attitudes toward medication in individuals with schizophrenia.
Methodology: Out of 52 subjects with schizophrenia, 43 were included in the study. The Positive and Negative Syndrome Scale (PANSS) and the ten-item Drug Attitude Inventory (DAI) were used to collect data. With a cut-off score of 4 on the DAI, subjects were divided into two groups: adherent and non-adherent. A paired t-test was also performed for comparison between two different assessment time points.
Results: During a 1-year study period with PP1M, both groups showed improvement in their symptoms. The change in DAI was significant and both groups showed improvement in DAI score. Subjects with a low DAI score at baseline showed shorter treatment duration compared with subjects with a higher score at baseline.
Conclusions: PP1M was effective in improving symptoms and positively changing attitudes toward medication in individuals with schizophrenia. Therefore, it may have promising effects cation in individuals with schizophrenia.
Schizophrenia, drug Attitude Inventory, paliperidone palmitate